MCID: DPY001
MIFTS: 48

Dupuytren Contracture

Categories: Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Dupuytren Contracture

MalaCards integrated aliases for Dupuytren Contracture:

Name: Dupuytren Contracture 56 25 17 71
Dupuytren Contracture 1 56 13 71
Dupuytren's Contracture 74 25
Contraction of Palmar Fascia 25
Familial Palmar Fibromatosis 25
Palmar Fascial Fibromatosis 25
Dupuytren Disease 25
Palmar Fibromas 25

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
progressive disorder
onset in fifth or sixth decade
earlier onset is associated with more aggressive disease course
male to female ratio is greater than 3:1
reduced penetrance
high risk of recurrence after surgery
associated with trauma and impaired wound repair (alcoholism, diabetes, substance abuse, liver disease)


HPO:

31
dupuytren contracture:
Inheritance autosomal dominant inheritance
Onset and clinical course progressive adult onset incomplete penetrance


Classifications:



External Ids:

OMIM 56 126900
ICD10 32 M72.0
MedGen 41 C0013312
UMLS 71 C0013312 C1851997

Summaries for Dupuytren Contracture

Genetics Home Reference : 25 Dupuytren contracture is characterized by a deformity of the hand in which the joints of one or more fingers cannot be fully straightened (extended); their mobility is limited to a range of bent (flexed) positions. The condition is a disorder of connective tissue, which supports the body's muscles, joints, organs, and skin and provides strength and flexibility to structures throughout the body. In particular, Dupuytren contracture results from shortening and thickening of connective tissues in the hand, including fat and bands of fibrous tissue called fascia; the skin is also involved. In men, Dupuytren contracture most often occurs after age 50. In women, it tends to appear later and be less severe. However, Dupuytren contracture can occur at any time of life, including childhood. The disorder can make it more difficult or impossible for affected individuals to perform manual tasks such as preparing food, writing, or playing musical instruments. Dupuytren contracture often first occurs in only one hand, affecting the right hand twice as often as the left. About 80 percent of affected individuals eventually develop features of the condition in both hands. Dupuytren contracture typically first appears as one or more small hard nodules that can be seen and felt under the skin of the palm. In some affected individuals the nodules remain the only sign of the disorder, and occasionally even go away without treatment, but in most cases the condition gradually gets worse. Over months or years, tight bands of tissue called cords develop. These cords gradually draw the affected fingers downward so that they curl toward the palm. As the condition worsens, it becomes difficult or impossible to extend the affected fingers. The fourth (ring) finger is most often involved, followed by the fifth (little), third (middle), and second (index) fingers. Occasionally the thumb is involved. The condition is also known as Dupuytren disease, and "Dupuytren contracture" most accurately refers to later stages when finger mobility is affected; however, the term is also commonly used as a general name for the condition. About one-quarter of people with Dupuytren contracture experience uncomfortable inflammation or sensations of tenderness, burning, or itching in the affected hand. They may also feel pressure or tension, especially when attempting to straighten affected joints. People with Dupuytren contracture are at increased risk of developing other disorders in which similar connective tissue abnormalities affect other parts of the body. These include Garrod pads, which are nodules that develop on the knuckles; Ledderhose disease, also called plantar fibromatosis, which affects the feet; scar tissue in the shoulder that causes pain and stiffness (adhesive capsulitis or frozen shoulder); and, in males, Peyronie disease, which causes abnormal curvature of the penis.

MalaCards based summary : Dupuytren Contracture, also known as dupuytren contracture 1, is related to peyronie disease and keloid disorder. An important gene associated with Dupuytren Contracture is DUPC1 (Dupuytren Contracture 1), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Anesthetics, Local and Anesthetics have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and bone, and related phenotypes are dupuytren contracture and joint contracture of the hand

OMIM : 56 Dupuytren contracture is the most common heritable disorder of connective tissue. It is a disease of the soft tissues of the palm and fingers characterized by a progressive thickening and shortening of the fascial structures that normally provide support to the glabrous skin of the palm. Although it can also be a sporadic disorder, the inherited form is most frequently observed among people of Nordic descent. There is a male: female ratio of greater than 3:1 (Hu et al., 2005). Dupuytren contracture has been associated with multiple fibroproliferative conditions, including Peyronie disease (171000), knuckle pads (149100), congenital generalized fibromatosis (228550), juvenile fibromatosis (228600), and frozen shoulder, suggesting a common underlying defect in wound repair (Hu et al., 2005). (126900)

Wikipedia : 74 Dupuytren's contracture is a condition in which one or more fingers become permanently bent in a flexed... more...

Related Diseases for Dupuytren Contracture

Diseases in the Dupuytren Contracture family:

Familial Dupuytren Contracture

Diseases related to Dupuytren Contracture via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 206)
# Related Disease Score Top Affiliating Genes
1 peyronie disease 30.7 TGFB1 DES
2 keloid disorder 30.5 TGFB1 SERPINH1 BMP6
3 marfan syndrome 29.8 TIMP2 TGFB1 DCN BMP6
4 carpal tunnel syndrome 29.6 VEGFA TGFB1 IL1B FGF2
5 fibrosarcoma 29.5 TIMP2 TGFB1 FGF2 DES
6 connective tissue disease 29.2 VEGFA SERPINH1 IL1B BMP6
7 familial dupuytren contracture 12.4
8 plantar fascial fibromatosis 11.8
9 ledderhose disease 11.7
10 alcohol dependence 10.6
11 liver cirrhosis 10.6
12 diabetes mellitus 10.6
13 complex regional pain syndrome 10.4
14 47,xyy 10.4
15 fibromatosis 10.4
16 cholecystolithiasis 10.4 TGFB1 BMP6
17 reflex sympathetic dystrophy 10.4
18 algoneurodystrophy 10.4
19 epilepsy 10.4
20 periarthritis 10.4
21 tenosynovitis 10.4
22 nephrogenic systemic fibrosis 10.3 TGFB1 DCN
23 hypertrophic scars 10.3 TGFB1 BMP6
24 cellular leiomyoma 10.3 DES BMP6
25 alcohol use disorder 10.3
26 enthesopathy 10.3
27 liver disease 10.3
28 arthritis 10.3
29 knuckle pads 10.3
30 peyronie's disease 10.3
31 pustulosis of palm and sole 10.3
32 psoriasis 10.3
33 chondromyxoid fibroma 10.3 TGFB1 DES
34 localized scleroderma 10.3 TGFB1 DCN BMP6
35 anthracosis 10.2 TGFB1 IL1B
36 eosinophilia-myalgia syndrome 10.2 TGFB1 BMP6
37 congenital epulis 10.2 NGFR DES
38 epulis 10.2 NGFR DES
39 fibromatosis, gingival, 1 10.2 TGFB1 SERPINH1
40 hand skill, relative 10.2
41 porphyria cutanea tarda 10.2
42 raynaud disease 10.2
43 rheumatoid arthritis 10.2
44 torticollis 10.2
45 myopathy, proximal, with ophthalmoplegia 10.2
46 gout 10.2
47 porphyria 10.2
48 spondylosis 10.2
49 ischemia 10.2
50 cataract 10.2

Graphical network of the top 20 diseases related to Dupuytren Contracture:



Diseases related to Dupuytren Contracture

Symptoms & Phenotypes for Dupuytren Contracture

Human phenotypes related to Dupuytren Contracture:

31
# Description HPO Frequency HPO Source Accession
1 dupuytren contracture 31 HP:0005679
2 joint contracture of the hand 31 HP:0009473

Symptoms via clinical synopsis from OMIM:

56
Skeletal Hands:
contractures of the fingers (especially fifth finger)

Muscle Soft Tissue:
thickening of the fascial structures of the palm and fingers
shortening of the fascial structures of the palm and fingers
plantar fibromatosis

Clinical features from OMIM:

126900

MGI Mouse Phenotypes related to Dupuytren Contracture:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.96 COL15A1 DES FBLN1 FGF2 IL1B NGFR
2 craniofacial MP:0005382 9.7 DCN FBLN1 IL1B NGFR SERPINH1 TGFB1
3 muscle MP:0005369 9.61 COL15A1 DCN DES FBLN1 FGF2 NGFR
4 skeleton MP:0005390 9.28 BMP6 DCN FBLN1 FGF2 IL1B NGFR

Drugs & Therapeutics for Dupuytren Contracture

Drugs for Dupuytren Contracture (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anesthetics, Local Phase 4
2 Anesthetics Phase 4
3
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
4
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
5
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
6 Hormones Phase 3
7 Immunologic Factors Phase 3
8 retinol Phase 3
9 Retinol palmitate Phase 3
10 glucocorticoids Phase 3
11 Triamcinolone diacetate Phase 3
12 Hormone Antagonists Phase 3
13 Immunosuppressive Agents Phase 3
14 triamcinolone acetonide Phase 3
15 Triamcinolone hexacetonide Phase 3
16 Calcium, Dietary Phase 3
17 Anesthetics, General Phase 3
18
Calcium Nutraceutical Phase 3 7440-70-2 271
19
Bupivacaine Approved, Investigational Phase 2 2180-92-9, 38396-39-3 2474
20
Ibuprofen Approved Phase 2 15687-27-1 3672
21
Adalimumab Approved Phase 2 331731-18-1 16219006
22 Analgesics Phase 2
23 Analgesics, Non-Narcotic Phase 2
24 Narcotics Phase 2
25 Opiate Alkaloids Phase 2
26 Antipyretics Phase 2
27 Cyclooxygenase Inhibitors Phase 2
28 Anti-Inflammatory Agents, Non-Steroidal Phase 2
29 Anti-Inflammatory Agents Phase 2
30 Antirheumatic Agents Phase 2
31
tannic acid Approved 1401-55-4
32
Benzocaine Approved, Investigational 94-09-7, 1994-09-7 2337
33
Acetaminophen Approved 103-90-2 1983
34
Oxycodone Approved, Illicit, Investigational 76-42-6 5284603
35
Hydromorphone Approved, Illicit 466-99-9 5284570
36 Analgesics, Opioid

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex Completed NCT01450397 Phase 4
2 The Efficacy and Safety of Xiaflex Injections for the Treatment of Thumb Cords in Dupuytren's Contractures Completed NCT01265420 Phase 4
3 Retreatment of Recurrent Contractures in Joints Effectively Treated With AA4500 (Collagenase Clostridium Histolyticum [XIAFLEX®/XIAPEX®]) in an Auxilium-sponsored Phase 3 Study in the United States, Australia, and Europe Completed NCT01498640 Phase 4
4 DupuytrEn Treatment EffeCtiveness Trial (DETECT): Prospective, Randomised, Controlled, Outcome Assessor-blinded, Three-armed Parallel 1:1:1, Multicenter Trial Comparing the Effectiveness and Cost of Collagenase Clostridium Histolyticum, Percutaneous Needle Fasciotomy and Limited Fasciectomy as Short-term and Long-term Treatment Strategies in Dupuytren's Contracture Recruiting NCT03192020 Phase 4 Collagenase Clostridium Histolyticum 2.9 MG/ML [Xiaflex]
5 Comparison of Collagenase Injection and Percutaneous Needle Aponeurotomy for Treatment of Dupuytren's Disease Recruiting NCT03000114 Phase 4 XIAFLEX
6 Prospektiv Randomisert Sammenlikning Mellom Percutan nålefasciotomi og Xiapex for Dupuytrens Kontraktur Recruiting NCT02476461 Phase 4 xiapex
7 A Randomized Controlled Trial (RCT) Comparing Clostridium Histolyticum With Needle Aponeurotomy. Active, not recruiting NCT02647619 Phase 4 Xiapex
8 Surgical Fasciectomy Versus Collagenase Injection in Treating Recurrent Dupuytren Disease: a Randomized Controlled Trial Enrolling by invitation NCT03406338 Phase 4 Collagenase Clostridium Histolyticum
9 A Post Market, Open-Label Study of the Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture Terminated NCT01226121 Phase 4
10 Phase III Study of AK160 in Patients With Dupuytren's Contracture Completed NCT01588353 Phase 3 Collagenase Clostridium Histolyticum
11 A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Dupuytren's Contracture Completed NCT00528606 Phase 3
12 Double-blind, Randomized Placebo Controlled Study of the Relative Safety and Efficacy of Collagenase Therapy in the Treatment of Residual-type Dupuytren's Disease. Completed NCT00260429 Phase 3
13 The Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Patients With Dupuytren's Contracture: a Randomized Controlled Study Completed NCT00565019 Phase 3 Triamcinolone Acetonide
14 A Phase 3, Open-Label Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease Completed NCT00528840 Phase 3
15 Prospective Open-Label Investigation Of The Non-surgical Treatment With Collagenase Clostridium Histolyticum (Xiapex) Completed NCT01229436 Phase 3 Xiapex
16 An Open-label Study to Assess the Safety and Efficacy of Concurrent Administration of Two Injections of AA4500 0.58 mg Into the Same Hand of Subjects With Multiple Dupuytren's Contractures Completed NCT01407068 Phase 3
17 A Phase 3, Open-Label Extension Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease Completed NCT00528424 Phase 3
18 Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease Completed NCT00014742 Phase 3 collagenase
19 A Phase 3b Open-label, Historically-controlled Study to Assess the Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures With Palpable Cords Completed NCT01674634 Phase 3
20 A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease Followed by an Open-Label Extension Phase Completed NCT00533273 Phase 3
21 Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing Completed NCT00931567 Phase 2, Phase 3
22 A Multi-Center, Randomized Controlled Trial Comparing The Clinical Effectiveness and Cost-Effectiveness of Collagenase Injection (Xiaflex) and Palmar Fasciectomy in the Management of Dupuytren's Disease Recruiting NCT02725528 Phase 3 collagenase injection
23 Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease Withdrawn NCT01776892 Phase 3 Collegenase injection
24 Distal Extremity (Wrist) Nerve Blocks With a Mixture of Liposome Bupivacaine + Bupivacaine Versus Bupivacaine Alone for Patients Having Dupuytren's Contracture Release: a Blinded Randomized Controlled Trial Unknown status NCT03106519 Phase 2 Liposome bupivacaine + bupivacaine
25 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) - a Randomized Trial Unknown status NCT01184586 Phase 2
26 Phase 2 Of Injectable Collagenase (Xiaflex) For Burns' Associated Contracture Unknown status NCT01237964 Phase 2 Xiaflex (FDA approved collagenase)
27 Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease Completed NCT00004409 Phase 2 collagenase
28 A Randomized Trial Comparing Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Outpatient Soft Tissue Hand Surgery Completed NCT03111186 Phase 2 Oxycodone Hcl 5Mg;Ibuprofen 400 mg;Acetaminophen 650 mg
29 A Phase 2a, Double-blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Effectiveness of AA4500 in the Treatment of Dupuytren's Disease Nodules Completed NCT02193828 Phase 2
30 A Multi-centre, Double Blind, Randomised, Placebo-controlled, Parallel Group, Phase II Trial to Determine the Efficacy of Intra-nodular Injection of Anti-TNF to Control Disease Progression in Early Dupuytren's Disease, With a Dose Response. Active, not recruiting NCT03180957 Phase 2 Adalimumab;Saline
31 A Phase 1, Open-Label Study to Assess the Pharmacokinetics and Safety of a Single Injection of AA4500 0.58 mg in Subjects With Dupuytren's Contracture Completed NCT00528931 Phase 1
32 The Effectiveness of Night Splinting After Collagenase Injection for Dupuytren's Contracture Unknown status NCT03031080
33 A Prospective Study to Validate Two New Patient Reported Outcome Measures for Dupuytren's Disease in Patients Treated With XIAFLEX Unknown status NCT01446432
34 Does Fibrosis Diathesis Influence the Recovery of Knee Mobility After Total Knee Replacement? Unknown status NCT02294890
35 Comparing Short-term Function and Pain After Treatment With Collagenase Clostridium Histolyticum or Percutaneous Needle Aponeurotomy for Dupuytren's Disease Unknown status NCT02301078 Collagenase clostridium histolyticum
36 A Non-Interventional Post Approval Commitment Study To Evaluate The Outcomes Of The Various Treatment Options For Dupuytren's Contracture Completed NCT01444729 Xiapex
37 Comparing Injectable Collagenase (CI) and Percutaneous Needle Fasciotomy (PNF) for Dupuytren's Contracture (DC) Affecting Proximal Interphalangeal Joints (PIP). A Randomised Controlled Trial Completed NCT01538017 Xiapex
38 Prospective Randomized Comparison of Dynamic Versus Static Splinting After Dupuytren's Contracture Release Completed NCT00575458
39 Collagenase Clostridium Histolytic is a Common Treatment of MCP and PIP Joint Contractures in Dupuytren Disease. A 1 to 4 Year Followup Study of 198 Joints Completed NCT03331926 Xiapex
40 Community Registry Study Evaluating Dupuytren's Contracture Treatment. A Prospective, Observational, Longitudinal, Multicenter Study of the Treatment Patterns and Outcomes in Patients With Dupuytren's Contracture. Completed NCT01715467
41 Health-Related Quality of Life in Patients With Dupuytren's Disease: A Prospective Cohort Study. Completed NCT00468949
42 CORDLESS- Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study Completed NCT00954746
43 Registry of Dupuytren's Contracture Treatment Outcomes Completed NCT01567397
44 The Role of Patient Factors, Surgical Factors and Hospital Factors Upon Patient Outcomes and NHS Costs in the Treatment of Upper Limb Musculoskeletal Conditions: Spatial and Iongitudinal Analysis of Routine Data Completed NCT03573765
45 Buildup of a Registry of Patient With M. Dupuytren and Validation of the Brief Michigan Hand Questionnaire Completed NCT01876498
46 Does Giving a Question Prompt List to Patients With Common Hand Conditions Improve Their Perceived Involvement in Care? A Randomized Controlled Trial Completed NCT03868449
47 Perforating Fat Injections for Plantar Fasciosis Completed NCT02855983
48 Hand Therapy or Not Following Collagenase Treatment for Dupuytren's Contracture? Recruiting NCT03580213
49 The Effects of Prophylactic Limited Palmar Fasciectomy on Surgical Outcomes and Scarring for Dupuytren's Contracture Patients With Pretendinous Cord - Prospective Randomized Clinical Study (Pilot) Recruiting NCT03155854
50 Efficacy of Post-contracture Release Radiation for the Treatment of Dupuytren's Disease Recruiting NCT04122313

Search NIH Clinical Center for Dupuytren Contracture

Genetic Tests for Dupuytren Contracture

Anatomical Context for Dupuytren Contracture

MalaCards organs/tissues related to Dupuytren Contracture:

40
Skin, Liver, Bone, Tongue

Publications for Dupuytren Contracture

Articles related to Dupuytren Contracture:

(show top 50) (show all 170)
# Title Authors PMID Year
1
Cytogenetic studies in Dupuytren contracture. 56 61
3414684 1988
2
A Dupuytren contracture family. 56 61
13470398 1957
3
Wnt signaling and Dupuytren's disease. 56
22047569 2011
4
Wnt signaling and Dupuytren's disease. 56
21732829 2011
5
Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. 56
16207209 2005
6
Familial leuconychia, knuckle pads, hearing loss, and palmoplantar hyperkeratosis: an additional family with Bart-Pumphrey syndrome. 56
8151643 1994
7
Familial hypodontia associated with Dupuytren's disease. 56
2091241 1990
8
Familial fibromatosis. 56
7307318 1981
9
Biochemistry and histology of the connective tissue of Dupuytren's disease lesions. 56
6768572 1980
10
Familial Dupuytren's contracture with predominantly female expression. 56
444771 1979
11
Chromosome abnormalities in Dupuytren's disease. 56
54801 1975
12
The share of heredity in the formation of Dupuytren's contracture. 56
4112400 1972
13
A family with Dupuytren's contracture. 56
5672291 1968
14
THE GENETIC FACTOR IN DUPUYTREN'S DISEASE. 56
14074318 1963
15
HEREDITY AND DUPUYTREN'S CONTRACTION. 56
20776252 1931
16
Office-Based Percutaneous Fasciotomy for Dupuytren Contracture. 61
32498955 2020
17
Return-to-Function Following Treatment of Dupuytren Contracture With Collagenase Clostridium Histolyticum Versus Fasciectomy. 61
32507053 2020
18
Percutaneous needle fasciotomy in Dupuytren contracture: a register-based, observational cohort study on complications in 3,331 treated fingers in 2,257 patients. 61
32056475 2020
19
Skin Expansion Due to the Dupuytren Cord Allows to Design Local Flaps to Facilitate Skin Closure in Severe Cases: The 3-flap: Surgical Technique and Clinical Evaluation. 61
31876775 2020
20
Risk Factors for Skin Tears Following Collagenase Clostridium histolyticum to Treat Dupuytren Contractures. 61
32546304 2020
21
Illness Perceptions of Patients With First Carpometacarpal Osteoarthritis, Carpal Tunnel Syndrome, Dupuytren Contracture, or Trigger Finger. 61
31812335 2020
22
Radiation Therapy for Benign Disease: Arteriovenous Malformations, Desmoid Tumor, Dupuytren Contracture, Graves Ophthalmopathy, Gynecomastia, Heterotopic Ossification, Histiocytosis. 61
31739945 2020
23
Tissue adaptation rate in the treatment of Dupuytren contracture. 61
30926179 2020
24
Using Tongue Depressors as a Technique to Aid Cord Localization During Collagenase Injection For Dupuytren Disease. 61
31738740 2019
25
Outcomes and Direct Costs of Needle Aponeurotomy, Collagenase Injection, and Fasciectomy in the Treatment of Dupuytren Contracture. 61
31537401 2019
26
[Distal-type Cervical Spondylolisthesis Muscular Atrophy in a Patient with Dupuytren Contracture: A Case Report]. 61
31722316 2019
27
Dupuytren contracture as a sign of systemic disease. 61
31864447 2019
28
Collagenase Clostridium Histolyticum Injection for Dupuytren Contracture: 2-Year Follow-up. 61
31475055 2019
29
A new finger-preserving procedure as an alternative to amputation in recurrent severe Dupuytren contracture of the small finger. 61
31288790 2019
30
Discussion: Collagenase Clostridium Histolyticum for Dupuytren Contracture: Comparing Single and Concurrent Injections. 61
30921133 2019
31
Factors Causing Prolonged Postoperative Symptoms Despite Absence of Complications After A1 Pulley Release for Trigger Finger. 61
30054030 2019
32
Variability of PROMIS Scores Across Hand Conditions. 61
30577995 2019
33
Percutaneous Needle Fasciotomy for Dupuytren Contracture. 61
31086724 2019
34
Ultrasound Features of Palmar Fibromatosis or Dupuytren Contracture. 61
30027660 2019
35
CHEIROARTHROPATHY: A COMMON DISORDER IN PATIENTS IN THE T1D EXCHANGE. 61
30383489 2019
36
Range of Motion Measurements of the Fingers Via Smartphone Photography. 61
30688093 2019
37
A post hoc analysis of Dupuytren contracture treated with collagenase Clostridium histolyticum across disease stages. 61
30039732 2018
38
Collagenase Clostridium Histolyticum Injection with Precise Needle Length Adjusted by Silicone Tube Interposition for Dupuytren Contracture. 61
30282547 2018
39
Complications of Treatment for Dupuytren Disease. 61
30012298 2018
40
Fasciectomy for Dupuytren Contracture. 61
30012295 2018
41
The Incidence of Complex Regional Pain Syndrome in Simultaneous Surgical Treatment of Carpal Tunnel Syndrome and Dupuytren Contracture. 61
28691512 2018
42
Dupuytren Disease: Is Collagenase Better Than Needling?: Commentary on an article by Joakim Strömberg, MD, et al.: "Percutaneous Needle Fasciotomy Versus Collagenase Treatment for Dupuytren Contracture. A Randomized Controlled Trial with a Two-Year Follow-up". 61
29975278 2018
43
Percutaneous Needle Fasciotomy Versus Collagenase Treatment for Dupuytren Contracture: A Randomized Controlled Trial with a Two-Year Follow-up. 61
29975270 2018
44
Night Orthosis After Surgical Correction of Dupuytren Contractures: A Systematic Review. 61
28867249 2017
45
Complications Following Collagenase Treatment for Dupuytren Contracture. 61
28635316 2017
46
Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial. 61
28854973 2017
47
Modified McCash Technique for Management of Dupuytren Contracture. 61
28259564 2017
48
Injectable Collagenase Versus Percutaneous Needle Fasciotomy for Dupuytren Contracture in Proximal Interphalangeal Joints: A Randomized Controlled Trial. 61
28473158 2017
49
Treatment of Recurrent Dupuytren Contracture in Joints Previously Effectively Treated With Collagenase Clostridium histolyticum. 61
28341067 2017
50
Treatment of Dupuytren Contracture With Injectable Collagenase Within the Veterans Affairs System. 61
27760243 2017

Variations for Dupuytren Contracture

Expression for Dupuytren Contracture

Search GEO for disease gene expression data for Dupuytren Contracture.

Pathways for Dupuytren Contracture

Pathways related to Dupuytren Contracture according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 VEGFA TIMP2 TGFB1 NGFR IL1B FGF2
2
Show member pathways
13.4 VEGFA TIMP2 TGFB1 NGFR IL1B FGF2
3
Show member pathways
13.26 TIMP2 TGFB1 NGFR IL1B FGF2 BMP6
4
Show member pathways
13.17 TIMP2 TGFB1 NGFR IL1B FGF2 BMP6
5
Show member pathways
12.91 TIMP2 TGFB1 NGFR FGF2 BMP6
6
Show member pathways
12.88 TIMP2 TGFB1 NGFR FGF2 COL15A1 BMP6
7 12.6 VEGFA TGFB1 NGFR IL1B FGF2
8
Show member pathways
12.47 TIMP2 TGFB1 NGFR IL1B FGF2 BMP6
9
Show member pathways
12.35 TIMP2 TGFB1 SERPINH1 FGF2 FBLN1 DCN
10 12.16 VEGFA TGFB1 FGF2 DCN
11
Show member pathways
12.01 TIMP2 TGFB1 NGFR IL1B FGF2 BMP6
12 11.9 VEGFA TGFB1 NGFR FGF2
13 11.88 TGFB1 NGFR IL1B
14 11.81 VEGFA TGFB1 IL1B FGF2
15 11.78 VEGFA TGFB1 IL1B
16 11.74 TGFB1 DCN BMP6
17 11.73 VEGFA TGFB1 IL1B
18 11.69 TIMP2 TGFB1 FGF2
19 11.6 TIMP2 TGFB1 FGF2 BMP6
20 11.53 TGFB1 IL1B FGF2
21 11.39 VEGFA TGFB1 FGF2
22 11.35 VEGFA TGFB1 FGF2
23 11.17 VEGFA TGFB1 SERPINH1 FGF2 BMP6
24 11.08 TGFB1 NGFR FGF2 DES DCN BMP6
25 11.02 VEGFA TGFB1 FGF2
26 10.96 VEGFA TIMP2 FGF2
27 10.7 TIMP2 TGFB1 IL1B FGF2 DES COL15A1
28 10.68 TGFB1 IL1B

GO Terms for Dupuytren Contracture

Cellular components related to Dupuytren Contracture according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.73 TIMP2 TGFB1 SERPINH1 FBLN1 DCN COL15A1
2 extracellular region GO:0005576 9.7 XDH VEGFA TIMP2 TGFB1 NGFR IL1B
3 extracellular matrix GO:0031012 9.63 VEGFA TIMP2 TGFB1 FBLN1 DCN COL15A1
4 secretory granule GO:0030141 9.5 VEGFA TGFB1 IL1B
5 extracellular space GO:0005615 9.36 XDH VEGFA TIMP2 TGFB1 SERPINH1 IL1B

Biological processes related to Dupuytren Contracture according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.06 VEGFA TGFB1 IL1B FGF2 DCN BMP6
2 negative regulation of gene expression GO:0010629 9.88 XDH VEGFA TGFB1 FGF2
3 positive regulation of cell proliferation GO:0008284 9.88 VEGFA TGFB1 IL1B FGF2 BMP6
4 cytokine-mediated signaling pathway GO:0019221 9.85 VEGFA TGFB1 IL1B FGF2
5 extracellular matrix organization GO:0030198 9.8 FGF2 FBLN1 DCN COL15A1
6 kidney development GO:0001822 9.78 VEGFA DCN BMP6
7 wound healing GO:0042060 9.74 TGFB1 FGF2 DCN
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 VEGFA TGFB1 BMP6
9 cellular response to mechanical stimulus GO:0071260 9.7 TGFB1 IL1B BMP6
10 negative regulation of protein phosphorylation GO:0001933 9.69 XDH TGFB1 FBLN1
11 cell migration involved in sprouting angiogenesis GO:0002042 9.64 VEGFA FGF2
12 positive regulation of histone acetylation GO:0035066 9.63 TGFB1 IL1B
13 negative regulation of vascular endothelial growth factor signaling pathway GO:1900747 9.63 XDH DCN
14 positive regulation of endothelial cell proliferation GO:0001938 9.63 VEGFA FGF2 BMP6
15 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.62 VEGFA TGFB1
16 membrane protein intracellular domain proteolysis GO:0031293 9.62 TGFB1 NGFR
17 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.61 VEGFA IL1B
18 positive regulation of epithelial cell proliferation GO:0050679 9.61 VEGFA TGFB1 BMP6
19 hyaluronan catabolic process GO:0030214 9.6 TGFB1 FGF2
20 positive regulation of SMAD protein signal transduction GO:0060391 9.59 TGFB1 BMP6
21 positive regulation of MAP kinase activity GO:0043406 9.58 VEGFA TGFB1 FGF2
22 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.54 VEGFA BMP6
23 positive regulation of blood vessel endothelial cell migration GO:0043536 9.54 VEGFA TGFB1 FGF2
24 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.5 TGFB1 NGFR FGF2
25 positive regulation of p38MAPK cascade GO:1900745 9.33 XDH VEGFA IL1B
26 negative regulation of adherens junction organization GO:1903392 9.26 VEGFA BMP6
27 positive regulation of vascular permeability GO:0043117 9.13 VEGFA TGFB1 BMP6
28 positive regulation of cell division GO:0051781 8.92 VEGFA TGFB1 IL1B FGF2

Molecular functions related to Dupuytren Contracture according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 VEGFA TGFB1 FGF2 FBLN1 DES CCT7
2 integrin binding GO:0005178 9.43 TIMP2 IL1B FGF2
3 growth factor activity GO:0008083 9.26 VEGFA TGFB1 FGF2 BMP6
4 cytokine activity GO:0005125 9.02 VEGFA TGFB1 IL1B FGF2 BMP6

Sources for Dupuytren Contracture

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....